Skip to main content
RVTY
NYSE Industrial Applications And Services

Revvity Q2 2026: 1% Revenue Growth, $46M Restructuring, and China Immunodiagnostics Divestiture

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$115.73
Mkt Cap
$12.911B
52W Low
$81.22
52W High
$118.3
52W Position info
42% above low
Off High info
2.2% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

RVTY sits 42% above its 52-week low of $81.22.

Summary

Revvity posted Q2 2026 revenue of $729.7M (+1% YoY) and GAAP EPS of $0.47. Restructuring charges of $35.5M pressured operating income, and the company announced the divestiture of its China Immunodiagnostics business.


Key Events · Earnings and Guidance · RVTY

  • Q2 Revenue Up 1%, EPS $0.47

    Revenue reached $729.7M, driven by 5% growth in Diagnostics, offsetting a 2% decline in Life Sciences. GAAP diluted EPS was $0.47, down from $0.46 a year ago.

  • Restructuring Charges Surge to $35.5M

    Restructuring and other costs hit $35.5M in Q2, up from $11.2M last year, as the company cut ~5% of its workforce and consolidated facilities to streamline operations.

  • Tariff Refunds Boost Gross Margin

    The company recorded $16.2M in tariff refunds in cost of revenue, helping gross margin expand 260 bps to 57.1%.

  • Divestiture of China Immunodiagnostics

    Subsequent to quarter-end, Revvity agreed to sell its China Immunodiagnostics business, which accounted for ~6% of FY2025 revenue. The deal is expected to close by end of 2027.


Analysis · RVTY · Industrial Applications And Services

Revvity's Q2 2026 results delivered a modest 1% revenue increase to $729.7M, but operating income fell as restructuring charges jumped to $35.5M for the quarter. The company is streamlining operations by cutting approximately 5% of its workforce, while $16.2M in tariff refunds provided a lift to gross margins. A subsequent agreement to divest the China Immunodiagnostics business—representing 6% of FY2025 revenue—signals a strategic pivot. The balance sheet remains solid with $1.0B in cash and a $1.5B undrawn credit facility, yet the restructuring and divestiture underscore a shift in focus toward profitability over growth.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1410 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RVTY was trading at $115.73 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $81.22 to $118.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RVTY - Latest Insights

RVTY
Nov 03, 2026, 8:16 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $167.00
Real-time Price: $150.83 info
Change: -$16.17 (-10%) info
Market Cap: $16.831B info
RVTY
Nov 03, 2026, 6:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $157.77
Real-time Price: $150.83 info
Change: -$6.94 (-4%) info
Market Cap: $16.831B info
RVTY
Sep 09, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $126.00
Real-time Price: $150.83 info
Change: +$24.83 (+20%) info
Market Cap: $16.831B info
RVTY
Aug 04, 2026, 6:51 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $115.00
Real-time Price: $150.83 info
Change: +$35.83 (+31%) info
Market Cap: $16.831B info
RVTY
Aug 04, 2026, 6:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $115.00
Real-time Price: $150.83 info
Change: +$35.83 (+31%) info
Market Cap: $16.831B info